Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2025 · 10-Q
Revenue$264.86M$264.86M+35.2% vs Q1 2024 Net Income$118.10M$118.10M+53.7% vs Q1 2024 EPS Diluted$0.93$0.93+55.0% vs Q1 2024 Operating Income$141,535,000+48.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Free Cash Flowderived$153,271,000+21.8% Margins · derivedOperating margin53.4%+4.7 pt vs Q1 2024
Net margin44.6%+5.4 pt vs Q1 2024
ended Mar 31, 2025 · filed May 6, 2025 · 36 d after period end